TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
30.76
-0.62 (-1.98%)
At close: Dec 5, 2025, 4:00 PM EST
30.63
-0.13 (-0.42%)
After-hours: Dec 5, 2025, 7:13 PM EST
TG Therapeutics Employees
TG Therapeutics had 338 employees as of December 31, 2024. The number of employees increased by 74 or 28.03% compared to the previous year.
Employees
338
Change (1Y)
74
Growth (1Y)
28.03%
Revenue / Employee
$1,573,663
Profits / Employee
$1,323,885
Market Cap
4.50B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TGTX News
- 7 days ago - TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 17 days ago - TG Therapeutics: Concerns About Slowing Growth And New Competition - Seeking Alpha
- 18 days ago - TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing - Seeking Alpha
- 4 weeks ago - TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows - Seeking Alpha
- 4 weeks ago - TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 5 weeks ago - TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI - GlobeNewsWire
- 2 months ago - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment - GlobeNewsWire